Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketoprofen Phase IV trials for headache claim, dysmenorrhea dosing suggested by cmte.

This article was originally published in The Tan Sheet

Executive Summary

KETOPROFEN PHASE IV TRIALS FOR HEADACHE, DYSMENORRHEA SUGGESTED by FDA's Arthritis and Nonprescription Drugs Advisory Committees at a July 14 joint meeting in Rockville, Md. Summarizing the committee's discussion of the headache indication, NDAC Chair Randy Juhl, PhD, University of Pittsburgh, stated that "the data isn't as clear as we would like it to be."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel